放射性配体治疗的全球市场

预计到 2030 年，全球放射性配体治疗市场规模将达到 120 亿美元

全球放射性配体治疗市场规模预计在2024年为100亿美元，预计2030年将达到120亿美元，2024年至2030年的复合年增长率为3.0%。前列腺癌是本报告分析的细分市场之一，预计其复合年增长率为2.5%，到分析期结束时将达到51亿美元。神经内分泌肿瘤细分市场在分析期间的复合年增长率预计为2.5%。

美国市场规模估计为 27 亿美元，中国市场预计复合年增长率为 5.6%

美国放射性配体治疗市场规模预计2024年达到27亿美元。作为世界第二大经济体，中国预计到2030年市场规模将达到23亿美元，在2024-2030年的分析期间内，复合年增长率为5.6%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为1.2%和2.3%。在欧洲，预计德国市场的复合年增长率为1.7%。

全球「放射性配体疗法」市场—主要趋势与驱动因素摘要

放射性配体疗法会重新定义癌症治疗模式吗？

放射性配体疗法 (RLT) 是一种标靶、微创的传统癌症治疗方法，被公认为癌症治疗的突破性方法。 RLT 将放射性同位素附着在特异性针对癌细胞的配体上，将放射线直接输送到癌症组织，同时不伤害健康组织。这种机制可产生精确的细胞毒性，同时减少全身性副作用，使 RLT 成为转移性癌症和抗治疗性癌症的突破性治疗方法。核准的治疗方法，如 Lutathera（用于治疗神经内分泌肿瘤）和 Pluvicto（用于治疗转移性前列腺癌），已显示出可显着提高生存率和生活品质。对肿瘤生物标记和受体谱的深入了解使得开发针对更广泛恶性肿瘤的新型放射性配体成为可能。随着精准医疗成为临床当务之急，放射性配体疗法正从小众选择发展成为晚期癌症治疗方法的核心组成部分。

同位素和配体开发方面的创新如何扩展 RLT 的能力？

放射性药物工程的进展正在迅速提高放射性配体治疗的安全性、有效性和治疗范围。螯合剂化学的创新正在提高镏-177、锕-225和钇-90等同位素的稳定性和结合亲和性。胜肽和抗体工程的进展也同步推进，提高了肿瘤选择性并延长了循环半衰期。研究人员目前正在开发可用于影像和治疗的双标靶配体和诊疗偶联物，从而促进即时治疗监测和剂量优化。新型放射性核种也被引入，以克服穿透深度和照射范围的局限性，使放射性核种治疗（RLT）对小型肿瘤和深部肿瘤均有效。这些创新有助于扩大放射性核种在先前无法治癒的癌症中的应用，并改善抗药性肿瘤的治疗效果。不断发展的同位素和配体套件包为RLT的更广泛应用和个性化奠定了基础。

临床基础设施和报销政策是否能够满足日益增长的 RLT 需求？

虽然放射性配体疗法的临床价值显而易见，但其推广在基础设施准备和监管途径方面仍面临挑战。放射性配体疗法 (RLT) 需要专门的设施来生产、安全处理和为患者提供治疗。同位素（尤其是α发射核素）的取得管道有限，导致许多地区出现供应链瓶颈。此外，将 RLT 整合到肿瘤学工作流程中需要核子医学、放射科和肿瘤科之间的协作，从而需要跨学科培训和方案製定。保险报销也仍然不一致，覆盖范围通常仅限于核准的适应症和特定地区。然而，全球卫生当局越来越认识到 RLT 在晚期癌症中的成本效益，从而增加了资金投入和政策支持。官民合作关係有助于扩大同位素供应和治疗基础设施。随着认知度的提高和监管协调的改善，物流障碍有望减少，RLT 的可及性也将扩大。

是什么推动了放射性配体治疗市场的加速成长？

放射性配体治疗市场的成长受到多种因素的驱动，这些因素源自于技术发展、肿瘤学需求和不断发展的医疗保健政策。从技术上讲，更稳定的同位素、最佳化的配体和治疗诊断模型的出现正在提高临床成功率并扩大应用范围。就最终用途趋势而言，晚期和抗药性癌症的发生率正在上升，而 RLT 对此带来了新的希望。製药公司正在积极投资 RLT 管道，核医学领域的併购正在推动创新。医疗保健系统越来越重视个人化、基于价值的护理，使 RLT 成为一种策略一致的选择。患者对微创、高效治疗的需求进一步加速了市场采用。全球监管机构也在简化核准途径，透过快速通道指定和资金奖励鼓励新开发。这些因素共同使 RLT 成为主流癌症治疗方法。

部分

适应症（前列腺癌、神经内分泌肿瘤、乳癌、其他适应症）；同位素（氟-18、镓-68、镏-177、其他同位素）；最终用户（医院和诊所、诊断中心、其他最终用户）

受访公司范例（总合42家公司）

• Accuray Incorporated
• Advanced Accelerator Applications
• ARTBIO
• AstraZeneca
• Bayer AG
• Curium Pharma
• Eli Lilly and Company
• Endocyte Inc.
• Fusion Pharmaceuticals
• ITM Isotope Technologies Munich SE
• Johnson & Johnson Services Inc.
• Lantheus Holdings, Inc.
• Molecular Partners AG
• Nanobiotix
• Novartis AG
• Orano Med
• Pfizer Inc.
• POINT Biopharma Global Inc.
• Precirix NV
• Telix Pharmaceuticals Limited

关税影响係数

全球产业分析师根据公司总部所在国家、製造地、进出口（成品和原始OEM）来预测其竞争地位的变化。这种复杂且多面向的市场动态预计将以多种方式影响竞争对手，包括人为提高销货成本、盈利下降、供应链重组以及其他微观和宏观市场动态。

全球产业分析师密切关注来自全球顶尖首席经济学家（14,949位）、智库（62家）以及贸易和产业协会（171家）的专家的意见，以评估其对生态系统的影响并应对新的市场现实。我们追踪了来自每个主要国家的专家和经济学家对关税及其对本国影响的看法。

全球产业分析师预计，这场动盪将在未来2-3个月内逐渐平息，新的世界秩序将更加清晰地建立。全球产业分析师正在即时追踪这些事态发展。

2025年4月：谈判阶段

在4月的报告中，我们将探讨关税对全球整体市场的影响，并提供区域市场调整。我们的预测是基于历史数据和不断变化的市场影响因素。

2025年7月：最终关税调整

在各国宣布最终重置后，客户将在 7 月收到免费更新，最终更新将包含明确的关税影响分析。

相互和双边贸易及关税影响分析：

美国<>中国<>墨西哥<>加拿大<>欧盟<>日本<>印度<>其他176个国家

领先的产业经济学家：全球产业分析师知识库追踪了 14,949 位经济学家，其中包括来自民族国家、智库、贸易和产业协会、大型企业以及各领域专家的最具影响力的首席经济学家，他们共用了这场前所未有的全球经济状况模式转移的影响。我们超过 16,491 份报告大多遵循基于里程碑的两阶段发布计划。

目录

第一章调查方法

第二章执行摘要

• 市场概览
• 主要企业
• 市场趋势和驱动因素
• 全球市场展望

第三章市场分析

• 美国
• 加拿大
• 日本
• 中国
• 欧洲
• 法国
• 德国
• 义大利
• 英国
• 西班牙
• 俄罗斯
• 其他欧洲国家
• 亚太地区
• 澳洲
• 印度
• 韩国
• 其他亚太地区
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲
• 中东
• 伊朗
• 以色列
• 沙乌地阿拉伯
• 阿拉伯聯合大公国
• 其他中东地区
• 非洲

第四章 竞赛

Global Radioligand Therapy Market to Reach US$12.0 Billion by 2030

The global market for Radioligand Therapy estimated at US$10.0 Billion in the year 2024, is expected to reach US$12.0 Billion by 2030, growing at a CAGR of 3.0% over the analysis period 2024-2030. Prostate Cancer Indication, one of the segments analyzed in the report, is expected to record a 2.5% CAGR and reach US$5.1 Billion by the end of the analysis period. Growth in the Neuroendocrine Tumors Indication segment is estimated at 2.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.7 Billion While China is Forecast to Grow at 5.6% CAGR

The Radioligand Therapy market in the U.S. is estimated at US$2.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.3 Billion by the year 2030 trailing a CAGR of 5.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR.

Global "Radioligand Therapy" Market - Key Trends & Drivers Summarized

Is Radioligand Therapy Redefining Cancer Treatment Paradigms?

Radioligand therapy (RLT) is gaining recognition as a breakthrough approach in oncology, offering a targeted and minimally invasive alternative to conventional cancer therapies. By binding radioactive isotopes to ligands that specifically target tumor cells, RLT delivers radiation directly to cancerous tissues while sparing healthy ones. This mechanism provides precise cytotoxicity with fewer systemic side effects, positioning RLT as a game-changer in treating metastatic and treatment-resistant cancers. Approved therapies like Lutathera (for neuroendocrine tumors) and Pluvicto (for metastatic prostate cancer) have demonstrated significant survival benefits and quality-of-life improvements. The growing understanding of tumor biomarkers and receptor profiles is enabling the development of new radioligands targeting a wider range of malignancies. As precision medicine becomes a clinical imperative, radioligand therapy is transitioning from a niche option to a core component of advanced oncology regimens.

How Are Innovations in Isotope and Ligand Development Expanding RLT Potential?

Advances in radiopharmaceutical engineering are rapidly enhancing the safety, efficacy, and reach of radioligand therapies. Innovations in chelator chemistry are improving the stability and binding affinity of isotopes like Lutetium-177, Actinium-225, and Yttrium-90. Parallel progress in peptide and antibody engineering is allowing for better tumor selectivity and longer circulatory half-lives. Researchers are now developing dual-targeting ligands and theranostic pairs that can be used for both imaging and therapy, facilitating real-time treatment monitoring and dose optimization. New radionuclides are also being introduced to overcome limitations of penetration depth and radiation range, making RLT effective for both small and deep-seated tumors. These innovations are helping to expand radioligand applications to previously untreatable cancers and improving outcomes in resistant tumor profiles. The evolving toolkit of isotopes and ligands is setting the stage for broader RLT adoption and personalization.

Can Clinical Infrastructure and Reimbursement Policies Keep Pace With Growing RLT Demand?

While radioligand therapy's clinical value is clear, its expansion is challenged by infrastructure readiness and regulatory pathways. RLT requires specialized facilities for radiopharmaceutical production, safe handling, and patient administration. Limited access to isotopes, especially alpha emitters, remains a supply chain hurdle in many regions. Moreover, the integration of RLT into oncology workflows demands collaboration between nuclear medicine, radiology, and oncology departments, necessitating cross-disciplinary training and protocol development. Reimbursement also remains inconsistent, with coverage often limited to approved indications or specific geographic regions. However, global health authorities are increasingly recognizing the cost-effectiveness of RLT in advanced cancer stages, leading to improved funding and policy support. Public-private partnerships are helping expand isotope supply and treatment infrastructure. As awareness grows and regulatory harmonization improves, logistical barriers are expected to diminish, unlocking wider RLT access.

What’s Powering The Radioligand Therapy Market’s Accelerated Growth?

The growth in the radioligand therapy market is driven by several factors rooted in technological development, oncological needs, and healthcare policy evolution. Technologically, the emergence of more stable isotopes, optimized ligands, and theranostic models is increasing clinical success rates and broadening applications. End-use trends highlight a rising incidence of late-stage and resistant cancers, where RLT offers a new line of hope. Pharmaceutical companies are aggressively investing in RLT pipelines, and M&A activity in the nuclear medicine space is fostering innovation. Healthcare systems are increasingly prioritizing personalized and value-based care, making RLT a strategically aligned option. Patient demand for minimally invasive, high-efficacy treatments is further accelerating market uptake. Global regulatory bodies are also streamlining approval pathways, with fast-track designations and funding incentives bolstering new development. Together, these factors are propelling RLT into the mainstream of cancer care.

SCOPE OF STUDY:

The report analyzes the Radioligand Therapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Prostate Cancer, Neuroendocrine Tumors, Breast Cancer, Other Indications); Isotope (Fluorine-18, Gallium-68, Lutetium-177, Other Isotopes); End-Use (Hospitals & Clinics, Diagnostic Centers, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• Accuray Incorporated
• Advanced Accelerator Applications
• ARTBIO
• AstraZeneca
• Bayer AG
• Curium Pharma
• Eli Lilly and Company
• Endocyte Inc.
• Fusion Pharmaceuticals
• ITM Isotope Technologies Munich SE
• Johnson & Johnson Services Inc.
• Lantheus Holdings, Inc.
• Molecular Partners AG
• Nanobiotix
• Novartis AG
• Orano Med
• Pfizer Inc.
• POINT Biopharma Global Inc.
• Precirix NV
• Telix Pharmaceuticals Limited

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Radioligand Therapy - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Targeted Cancers Propels Demand for Radioligand Therapy Solutions
  • Expansion of Theranostics Enhances the Appeal of Dual Diagnostic and Treatment Approaches
  • Increased FDA and EMA Approvals for Radioligand-Based Therapies Accelerate Market Entry
  • Strong Pipeline of Oncology-Focused Radiopharmaceuticals Sustains Long-Term Growth
  • Partnerships Between Pharma Giants and Nuclear Medicine Innovators Strengthen Commercialization
  • Breakthroughs in Ligand Development and Target Specificity Improve Clinical Outcomes
  • Growing Integration in Advanced Prostate and Neuroendocrine Tumor Treatment Protocols Drives Adoption
  • Radioligand Therapy's Lower Side Effect Profile Strengthens Its Role in Precision Medicine
  • Manufacturing and Distribution Challenges for Radioisotopes Create Supply Bottlenecks
  • Rising Investment in Radiopharmaceutical CDMOs Expands Production Capacity and Market Reach
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Radioligand Therapy Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Radioligand Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Radioligand Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Radioligand Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Neuroendocrine Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Neuroendocrine Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Neuroendocrine Tumors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Diagnostic Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Fluorine-18 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Fluorine-18 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Fluorine-18 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Gallium-68 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Gallium-68 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Gallium-68 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Lutetium-177 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Lutetium-177 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Lutetium-177 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Other Isotopes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Other Isotopes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Other Isotopes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Radioligand Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• JAPAN
  • Radioligand Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• CHINA
  • Radioligand Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 65: China Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• EUROPE
  • Radioligand Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Radioligand Therapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Radioligand Therapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Radioligand Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• FRANCE
  • Radioligand Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 86: France Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• GERMANY
  • Radioligand Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Radioligand Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 113: UK Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Radioligand Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Radioligand Therapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Radioligand Therapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Radioligand Therapy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Radioligand Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• INDIA
  • Radioligand Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 170: India Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Radioligand Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Radioligand Therapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Radioligand Therapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Radioligand Therapy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Radioligand Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Radioligand Therapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Radioligand Therapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Radioligand Therapy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• AFRICA
  • Radioligand Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030

IV. COMPETITION